Will Big Pharma get the bug for microbiome therapies?
The microbiome therapeutics field is dominated by many innovative small and medium-sized enterprises (SMEs), all focused on driving the development of a single or a small pipeline of biotherapeutics. This has resulted in an impressive range of innovative products in development, often targeting conditions which conventional “small molecule” drug discovery projects have failed to adequately address.
While we are seeing growing engagement from ‘Big Pharma’, it is difficult to conclude that it has fully embraced the field. In 2018 we saw the first acquisition of a microbiome company, with the purchase of Rebiotix by Ferring. However, most Big Pharma is perhaps more tentatively venturing into the microbiome field via collaborations (eg, MSD and 4D Pharma, Takeda and Finch Therapeutics).
Is this a problem? Possibly not. However, what Big Pharma does have vast amounts of experience in is getting products approved and to the market. More engagement from Big Pharma may make it easier and faster to establish a “well-trodden” path to market for microbiome-related therapeutics, potentially making it easier for all in the field to get products to market. But what is most likely to tempt Big Pharma to engage even more with the microbiome field?
The options
The options can roughly be split into three categories:
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk